Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Quest Pharmatech ( (TSE:QPT) ).
Quest PharmaTech Inc. announced the re-election of four directors to its Board and the reappointment of its auditors at its recent annual general meeting. The company also granted 1,900,000 stock options to its directors and officers, which are subject to TSX Venture Exchange approval. These developments are part of Quest’s strategy to enhance shareholder value and strengthen its governance structure.
More about Quest Pharmatech
Quest PharmaTech Inc. is a Canadian-based biopharmaceutical company publicly traded on the TSX Venture Exchange. It focuses on developing products to improve quality of life through investee companies and proprietary technologies. The company is advancing its proprietary MAb-AR9.6 targeting MUC16 as theranostic agents for cancer, currently in late preclinical stage development. Quest also holds significant ownership interests in OncoQuest Inc. and OncoVent, which are involved in developing immunotherapeutic products for cancer.
Average Trading Volume: 30,914
Technical Sentiment Signal: Sell
Current Market Cap: C$5.92M
For a thorough assessment of QPT stock, go to TipRanks’ Stock Analysis page.